Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats

[en] Somatostatin analogs are widely used to treat conditions associated with hormonal hypersecretion such as acromegaly and metastatic neuroendocrine tumors. First generation somatostatin analogs, such as octreotide and lanreotide, have high affinity for somatostatin receptor subtype 2 (SSTR2), but have incomplete efficacy in many patients. Pasireotide targets multiple SSTRs, having the highest affinity for SSTR5, but causes hyperglycemia and diabetes mellitus in preclinical and clinical studies. AP102 is a new somatostatin analogs with high affinity at both SSTR2 and SSTR5. We aimed to characterize the effects of AP102 vs. pasireotide on random and dynamic glucose levels, glucoregulatory hormone concentrations and growth axis measures in healthy Sprague-Dawley rats.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Tarasco, Erika

Seebeck, Petra

Pfundstein, Svende

Daly, Adrian ; Université de Liège > Département des sciences cliniques > Endocrinologie

Eugster, Philippe J.

Harris, Alan G.

Grouzmann, Eric

Lutz, Thomas A.

Boyle, Christina N.

Language :

English

Title :

Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats

Publication date :

18 August 2017

Journal title :

Endocrine

ISSN :

1355-008X

eISSN :

1559-0100

Publisher :

Humana Press, Totowa, United States - New Jersey

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://doi.org/10.1007/s12020-017-1386-2

Available on ORBi :

since 18 August 2017

Statistics

Number of views

61 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest. 119(11), 3189–3202 (2009). doi:10.1172/JCI39375
L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). doi:10.1210/jc.2014-2700
J.D. Carmichael, V.S. Bonert, M. Nuno, D. Ly, S. Melmed, Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J. Clin. Endocrinol. Metab. 99(5), 1825–1833 (2014). doi:10.1210/jc.2013-3757
A. Colao, R.S. Auriemma, R. Pivonello, L. Kasuki, M.R. Gadelha, Interpreting biochemical control response rates with first-generation somatostatin analogs in acromegaly. Pituitary 19(3), 235–247 (2016). doi:10.1007/s11102-015-0684-z
H.A. Schmid, Pasireotide (SOM230): development, mechanism of action and potential applications. Mol. Cell. Endocrinol. 286(1-2), 69–74 (2008). doi:10.1016/j.mce.2007.09.006
M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94(1), 115–122 (2009). doi:10.1210/jc.2008-1008
S. Petersenn, A.J. Farrall, C. De Block, S. Melmed, J. Schopohl, P. Caron, R. Cuneo, D. Kleinberg, A. Colao, M. Ruffin, K. Hermosillo Resendiz, G. Hughes, K. Hu, A. Barkan, Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 17(2), 132–140 (2014). doi:10.1007/s11102-013-0478-0
S. Lesche, D. Lehmann, F. Nagel, H.A. Schmid, S. Schulz, Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94(2), 654–661 (2009). doi:10.1210/jc.2008-1919
A. Lehmann, A. Kliewer, D. Schutz, F. Nagel, R. Stumm, S. Schulz, Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor. Mol. Cell. Endocrinol. 387(1–2), 44–51 (2014). doi:10.1016/j.mce.2014.02.009
A. Mohamed, M.P. Blanchard, M. Albertelli, F. Barbieri, T. Brue, P. Niccoli, J.R. Delpero, G. Monges, S. Garcia, D. Ferone, T. Florio, A. Enjalbert, V. Moutardier, A. Schonbrunn, C. Gerard, A. Barlier, A. Saveanu, Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr. Relat. Cancer 21(5), 691–704 (2014). doi:10.1530/ERC-14-0086
M.D. Bronstein, M. Fleseriu, S. Neggers, A. Colao, M. Sheppard, F. Gu, C.C. Shen, M. Gadelha, A.J. Farrall, K. Hermosillo Resendiz, M. Ruffin, Y. Chen, P. Freda, C.S.G. Pasireotide, Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study. BMC Endocr. Disord. 16, 16 (2016). doi:10.1186/s12902-016-0096-8
H.A. Schmid, J. Brueggen, Effects of somatostatin analogs on glucose homeostasis in rats. J. Endocrinol. 212(1), 49–60 (2012). doi:10.1530/JOE-11-0224
R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan, S. Mudaliar, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98(8), 3446–3453 (2013). doi:10.1210/jc.2013-1771
A. Breitschaft, K. Hu, K. Hermosillo Resendiz, C. Darstein, G. Golor, Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res. Clin. Pract. 103(3), 458–465 (2014). doi:10.1016/j.diabres.2013.12.011
A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, B.S.G. Pasireotide, A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012). doi:10.1056/NEJMoa1105743
A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Resendiz, M. Ruffin, Y. Chen, M. Sheppard, C.S.G. Pasireotide, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99(3), 791–799 (2014). doi:10.1210/jc.2013-2480
M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, C.S.G. Pasireotide, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomized, phase 3 trial. Lancet Diabetes Endocrinol. 2(11), 875–884 (2014). doi:10.1016/S2213-8587(14)70169-X
Y. Reznik, J. Bertherat, F. Borson-Chazot, T. Brue, P. Chanson, C. Cortet-Rudelli, B. Delemer, A. Tabarin, S. Bisot-Locard, B. Verges, Management of hyperglycemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab. 39(1), 34–41 (2013). doi:10.1016/j.diabet.2012.10.005
A. Colao, C. De Block, M.S. Gaztambide, S. Kumar, J. Seufert, F.F. Casanueva, Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2), 180–186 (2014). doi:10.1007/s11102-013-0483-3
J.M. Silverstein, Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary 19(5), 536–543 (2016). doi:10.1007/s11102-016-0734-1
S.B. Moore, J. van der Hoek, A. de Capua, P.M. van Koetsveld, L.J. Hofland, S.W. Lamberts, M. Goodman, Discovery of iodinated somatostatin analogs selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells. J. Med. Chem. 48(21), 6643–6652 (2005). doi:10.1021/jm050376t
G. Weckbecker, U. Briner, I. Lewis, C. Bruns, SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143(10), 4123–4130 (2002)
J.M. Egan, C. Montrose-Rafizadeh, Y. Wang, M. Bernier, J. Roth, Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135(5), 2070–2075 (1994). doi:10.1210/endo.135.5.7956929
H. Sandhu, S.R. Wiesenthal, P.E. MacDonald, R.H. McCall, V. Tchipashvili, S. Rashid, M. Satkunarajah, D.M. Irwin, Z.Q. Shi, P.L. Brubaker, M.B. Wheeler, M. Vranic, S. Efendic, A. Giacca, Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48(5), 1045–1053 (1999)
D.A. D’Alessio, S.E. Kahn, C.R. Leusner, J.W. Ensinck, Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin. Invest. 93(5), 2263–2266 (1994). doi:10.1172/JCI117225
A. Pawlikowska-Haddal, P. Cohen, D.M. Cook, How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children? Pituitary 15(2), 126–134 (2012). doi:10.1007/s11102-011-0343-y
S.W. Lamberts, T. Verleun, J.M. Zuiderwijk, R. Oosterom, The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion. Acta Endocrinol. 115(2), 196–202 (1987)
R.A. Feelders, C. de Bruin, A.M. Pereira, J.A. Romijn, R.T. Netea-Maier, A.R. Hermus, P.M. Zelissen, R. van Heerebeek, F.H. de Jong, A.J. van der Lely, W.W.de Herder, L.J.Hofland,S.W.Lamberts,Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N. Engl. J. Med. 362(19), 1846–1848 (2010) 10.1056/NEJMc1000094
S.K. Shah, S. He, L. Guo, Q. Truong, H. Qi, W. Du, Z. Lai, J. Liu, T. Jian, Q. Hong, P. Dobbelaar, Z. Ye, E. Sherer, Z. Feng, Y. Yu, F. Wong, K. Samuel, M. Madiera, B.V. Karanam, V.B. Reddy, S. Mitelman, S.X. Tong, G.G. Chicchi, K.L. Tsao, D. Trusca, Y. Feng, M. Wu, Q. Shao, M.E. Trujillo, G.J. Eiermann, C. Li, M. Pachanski, G. Fernandez, D. Nelson, P. Bunting, P. Morissette, S. Volksdorf, J. Kerr, B.B. Zhang, A.D. Howard, Y.P. Zhou, A. Pasternak, R.P. Nargund, W.K. Hagmann, Discovery of MK-1421, a potent, selective sstr3 antagonist, as a development candidate for Type 2 Diabetes. ACS Med. Chem. Lett. 6(5), 513–517 (2015). doi:10.1021/ml500514w
A. Petrich, A. Mann, A. Kliewer, F. Nagel, A. Strigli, J.C. Martens, F. Poll, S. Schulz, Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor. Mol. Endocrinol. 27(4), 671–682 (2013). doi:10.1210/me.2012-1329
S.L. Samson, Pasireotide in acromegaly: an overview of current mechanistic and clinical data. Neuroendocrinology 102(1-2), 8–17 (2015). doi:10.1159/000381460
R. Cescato, K.A. Loesch, B. Waser, H.R. Macke, J.E. Rivier, J.C. Reubi, A. Schonbrunn, Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol. Endocrinol. 24(1), 240–249 (2010). doi:10.1210/me.2009-0321